Alkem Laboratories Ltd

Stage 4 · Declining · week 4

As of 9 Oct 2026, Alkem Laboratories is in Stage 4 — declining, a downtrend, in week 4 (since 10 Sep 2026). It closed at ₹5,279, 9.7% below its 52-week high and below its 200-day average, which is falling. In Health Care, 44.6% of stocks are in Stage 2.

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. More about the company

₹5,279
+0.56% today
₹63,118 Cr · Large cap
Market Neutral — FadingHealth Care 44.6% in Stage 2-2.6 pts / 20dPharmaceuticals 51.3%-0.4 pts

Pro read

Pro

Our read

Declining — below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ALKEM early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-9.7%
₹5,087.5 lo₹5,842.9 hi
9.7% below 52W high — failed near resistance
In Stage 4, distance from the 52W high reflects ongoing decline — not a discount. Avoid catching falling knives.
Stage Maturity
Week 4
1w13w26w
Week 4 — early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure — there's no 'bottom' time to buy.
vs 200 DMA
-3.5%
200 DMA: ₹5,467.7 · sloping down
In Stage 4, the stock is below its 200 DMA — the hallmark of a downtrend. No long positions warranted until this reverses structurally.
Rel Volume
0.65x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low volume bounces are typical — they lack real buyers and should not be mistaken for reversals.
Trend Health
→
MA20 flat · -0.0% vs MA50 -2.6%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
+1.9%
3M
-6.9%
6M
+0.6%
YTD
-5.4%
1Y
-1.9%
Sector
Health Care
↓ Peaking
Stage 2%
44.6%
20d Δ
-2.6pp
1M return
-4.9%
3M return
+0.2%
Sector Stage-2 % · last 20 days
Sector has 74 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
→ Flat
Stage 2%
51.3%
20d Δ
-0.4pp
1M return
-4.2%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Industry has 58 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Stage Cycle Timeline2023-07-13 → 2026-10-09
S2 20w
S2 23w
S4 15w
S2 28w
2023-07-132026-10-09
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 12w → S3 5w → S2 20w → S3 9w → S2 23w → S3 9w → S4 15w → S1 8w → S4 8w → S1 2w → S2 28w → S3 6w → S4 10w → S1 4w → S2 4w → S4 4w current
Total tracked: 168 weeks across 16 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-08-13
3 appearances in last 60 days. First seen: 2024-06-07.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-09S4
Wk 4 · Vol 0.65x
2026-10-08S4
Wk 4 · Vol 1.98x
2026-10-07S4
Wk 4 · Vol 1.46x
2026-10-06S4
Wk 4 · Vol 0.45x
2026-10-05S4
Wk 4 · Vol 0.74x
2026-10-01S4
Wk 3 · Vol 2.15x
2026-09-30S4
Wk 3 · Vol 1.10x
2026-09-29S4
Wk 3 · Vol 1.87x
2026-09-28S4
Wk 3 · Vol 0.78x
2026-09-25S4
Wk 3 · Vol 0.22x
2026-09-24S4
Wk 2 · Vol 1.26x
2026-09-23S4
Wk 2 · Vol 1.01x
Sector Peers — Stage 2All →
BAFNAPH
wk 18 · 0.0% from hi
8.6
ZIMLAB
wk 22 · 0.0% from hi
8.3
KILITCH
wk 2 · -7.3% from hi
8.3
SMSPHARMA
wk 3 · -8.0% from hi
8.3
RPGLIFE
wk 16 · -12.0% from hi
7.6
Moving averages & range
50 DMA
₹5,360
200 DMA
₹5,467.7
52W High
₹5,842.9
52W Low
₹5,087.5
5D Low
₹5,192.5
Resistance levels (recent highs)
20d High
₹5,466.5
60d High
₹5,816.5
120d High
₹5,816.5
250d High
₹5,842.9
Next resistance
+3.6%
to 20d High
Ask the Market AI about ALKEMAsk →
P/E (TTM)
27.5
Forward 28.9
Earnings Growth (YoY)
+1.6%
Revenue +10.7%
Dividend Yield
0.95%
P/B 4.9
About this companyHealth Care· Pharmaceuticals

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastroenterology, pain management, iron deficiency, diabetology, central nervous system, anti-osteoporosis, gynecology, respiratory, ophthalmology, rheumatology, urology, dermatology, cardiology, neurology, and oncology. It also provides vitamins, minerals, and nutrients; cough syrups, hepatoprotective tonic, anti-dandruff shampoo, mouth wash, pregnancy detection kits, and condoms; and anti-bloating syrups, tablets, and powder. The company was incorporated in 1973 and is headquartered in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-09. Past data patterns are not indicative of future results. This page is a data analytics tool only.